Introduction B-blockers are regarded as beneficial pharmacologic agents in cardiac care,
but their role in the acute setting remains ambiguous. Increasing evidence supports the …

This article provides a state-of-the-art review on landiolol, a medication that was recently
submitted for 7 approvals. Focusing on its pharmacology, pharmacokinetics, and …

Landiolol is an ultra-short-acting, selective β1-adrenergic receptor blocker that was
originally approved in Japan for the treatment of intraoperative tachyarrhythmias. It has …

Background: Landiolol, a highly cardioselective agent with a short half-life (2.4–4 min), is
commonly used as a perfusor or bolus application to treat tachycardic arrhythmia. Some …

Landiolol is an ultra-short-acting, selective ß1-adrenergic receptor blocker that was
originally approved by Japan for the treatment of intraoperative tachyarrhythmias. It has …

Hintergrund: Landiolol ist ein ultrakurzwirksamer hochselektiver Beta-1-Blocker, dessen
Einsatzbereich nicht-kompensatorische supraventrikulären Tachykardien im peri-und …